News & events

News & events

Filter by:
  • NewsScientific publications

VarmX announces publication of sensitive coagulation assays to assess restoration of coagulation using VMX-C001 in the presence of Factor Xa inhibitors

Key Highlights The collaborative study with Coagulation Profile BV, Maastricht University and Leiden University Medical Center has been accepted for...

  • News

VarmX and Rentschler Biopharma partner to advance novel coagulation therapy toward Phase 3 and commercialization

VarmX and Rentschler Biopharma expand collaboration from early development to late‑stage and commercial manufacturing of VMX-C001 VMX‑C001 builds on strong...

  • News

VarmX to Present New Data on Lead Compound, VMX-C001, at the ISTH 2021 Virtual Congress

VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces that new...
  • News

VarmX appoints Dr. Jan Öhrström as CEO, and Dr. Alex Gold to Supervisory Board

VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces the appointment...
  • News

VarmX appoints Dr. Gerard Short as Chief Medical Officer

VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces the appointment...
  • Scientific publications

VMX-C001 is a Bypassing Agent for FXa-inhibiting DOACs and Displays a Favorable Pharmacokinetic and Pharmacodynamic Profile

Reversal of anticoagulation is important for safe usage of oral factor (F)Xa-inhibiting direct oral anticoagulants (FXa-DOACs).

...
  • News

VarmX raises € 32 million series B financing

VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces the completion...
  • News

VarmX raises € 12.5 million to develop VMX-COO1

VarmX, Leiden based biotech company focusing on the development of therapies in the field of hemostasis and thrombosis, today announced...
  • News

Engineered factor Xa variants retain procoagulant activity independent of direct factor Xa inhibitors

VarmX announces publication in Nature Communications of groundbreaking snake venom inspired approach to restore blood clotting in patients using anticoagulants...
  • Scientific publications

Engineered factor Xa variants retain procoagulant activity independent of direct factor Xa inhibitors

The absence of an adequate reversal strategy to prevent and stop potential life-threatening bleeding complications is a major drawback to...

  • News

VarmX raises seed capital for development of VMX-C001

VarmX, a Dutch, Leiden based biotech company focusing on the development of therapies in the field of hemostasis and thrombosis,...

VMX-C001: Transforming the treatment of bleeding in patients taking Factor Xa DOACs

Portfolio